{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 42,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 13,
  "notes": "Includes footnotes explaining abbreviations and specific financial exclusions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/5",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.93,
        "x": 0.035,
        "y": 0.275
      },
      "kind": "list",
      "text": "Total revenue +18%, incl. 9% from the pandemic COVID-19 vaccine. Total revenue excl. vaccine +9%\nQ2 growth 12% excl. vaccine\nGrowth: Oncology +15% and New CVRM +16%. Respiratory & Immunology +6%. Emerging markets +21%\nCore operating profit +20%, supported by core OOI (+115%)\nCore EPS $2.53 (+27%), incl. 14% tax rate. Impact of pandemic vaccine $(0.04)\nPipeline news accelerated, incl. close-to-market opportunities\nESG: large boost in pandemic vaccine; about one billion doses released for supply as of today across the network of collaborators\nAlexion acquisition now closed; consolidation well underway\n2021 guidance updated: total revenue is expected to increase by a low-twenties percentage, accompanied by a faster growth in core EPS to $5.05 to $5.40",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "619aeed3-f13c-4aa2-9fd9-78f41409b9bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.87,
        "x": 0.035,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for first-half (H1) 2021, unless stated otherwise. Guidance at CER and excludes the pandemic COVID-19 vaccine. 1. Coronavirus disease; an infectious disease caused by a newly discovered coronavirus 2. New Cardiovascular, Renal & Metabolism comprising Farxiga, Brilinta, Diabetes and Renal 3. Other operating income 4. Earnings per share 5. Environmental, social and (corporate) governance (topics).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43e6ac71-b527-4963-8a9b-d5794dbf9fd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.13,
        "x": 0.035,
        "y": 0.225
      },
      "kind": "title",
      "text": "Key highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5820bd03-170e-4313-8109-8dc227068835",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.095,
        "w": 0.535,
        "x": 0.035,
        "y": 0.045
      },
      "kind": "title",
      "text": "H1 2021: growth profile enhanced",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2928b2e-6751-4ae4-b240-3d73d086b05e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "069591e7-05e3-4d0f-af08-2fceb5f12d02",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The document starts with an overview of H1 2021 results and key takeaways",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}